提升TIMM17A和NMT1的联合表达与非小细胞肺癌的生存率差有关
Alfred A Chan1, Kamya Sankar2, Karen L Reckamp2
1The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, 1124 West Carson Street, Torrance, CA, 90502, USA.
Scientific reports
|October 13, 2025
概括
具有STK11/KEAP1突变的肺癌对KRAS向疗法的耐药性呈现. 通过向TIMM17A,N-myristoyltransferase抑制剂显示出有希望的结果,提供了新的治疗策略.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 遗传学 遗传学 是一个
背景情况:
- 具有KRAS突变和同时发生的STK11/KEAP1突变的肺癌表现出内在的治疗耐药性.
- 在异种移植模型中,N-myristoyltransferase (NMT) 抑制剂在减少瘤生长方面表现出临床前的有效性.
研究的目的:
- 研究NMT1和TIMM17A在KRAS突变肺癌中的作用.
- 探索NMT1和TIMM17A表达和肺腺癌 (LUAD) 的临床结果之间的关联.
主要方法:
- 利用癌症基因组图谱 (TCGA) 数据进行分析.
- 采用考克斯回归模型来评估基因表达和生存终点 (OS,DSS,DFS) 之间的关系.
主要成果:
- 在LUAD组织中,NMT1和TIMM17A的高联合表达与总生存率 (OS),疾病特异性生存率 (DSS) 和无疾病生存率 (DFS) 显著下降相关.
- 较高的NMT1表达与较差的OS有关,特别是在表达TIMM17A高的瘤中.
结论:
- 一个新的NMT1/TIMM17A轴被确定为肺癌的潜在预后生物标志物.
- 这一轴代表了对具有STK11/KEAP1共同突变的KRAS突变非小细胞肺癌 (NSCLC) 的有前途的治疗标.
更多相关视频
07:47Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies
Published on: September 15, 2023
2.2K
09:40Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer
Published on: August 2, 2024
3.2K
相关概念视频
lncRNA - Long Non-coding RNAs
9.8K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
9.8K
mTOR Signaling and Cancer Progression
4.6K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
4.6K
Tumor Progression
7.2K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.2K
